CLAIM CARD
Within the corpus, the evidence shows broad agreement on the direction of cardiometabolic benefit, though the specific interventions and populations differ. By contrast, while all point toward improvement, the heterogeneity in interventions (walking vs. diet vs. multifactorial lifestyle change), study designs (RCT vs. meta-analysis vs. observational), and target populations (postmenopausal women vs. CKD patients vs. older adults with metabolic disease) precludes a unified quantitative estimate for aspirin's role. This underscores the need for focused RCTs on aspirin's specific geroprotective effects.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024